US 12,083,249 B2
Delivery of hydrophobic active agent particles
Joram Slager, St. Louis Park, MN (US); Toni M. Heyer, St. Louis Park, MN (US); and David E. Babcock, Brooklyn Park, MN (US)
Assigned to Surmodics, Inc., Eden Prairie, MN (US)
Filed by Surmodics, Inc., Eden Prairie, MN (US)
Filed on Dec. 19, 2022, as Appl. No. 18/084,247.
Application 18/084,247 is a continuation of application No. 16/847,272, filed on Apr. 13, 2020, granted, now 11,529,440.
Application 16/847,272 is a continuation of application No. 15/850,010, filed on Dec. 21, 2017, granted, now 10,617,793, issued on Apr. 14, 2020.
Application 15/850,010 is a continuation of application No. 14/609,270, filed on Jan. 29, 2015, granted, now 9,861,727, issued on Jan. 9, 2018.
Application 14/609,270 is a continuation in part of application No. 13/793,390, filed on Mar. 11, 2013, granted, now 10,213,529, issued on Feb. 26, 2019.
Application 13/793,390 is a continuation in part of application No. 13/469,844, filed on May 11, 2012, granted, now 9,757,497, issued on Sep. 12, 2017.
Claims priority of provisional application 61/488,582, filed on May 20, 2011.
Prior Publication US 2023/0338622 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 29/08 (2006.01); A61K 31/337 (2006.01); A61K 31/713 (2006.01); A61K 47/34 (2017.01); A61L 29/14 (2006.01); A61L 29/16 (2006.01); A61M 25/10 (2013.01); C12N 15/113 (2010.01); A61K 9/50 (2006.01)
CPC A61L 29/085 (2013.01) [A61K 31/337 (2013.01); A61K 31/713 (2013.01); A61K 47/34 (2013.01); A61L 29/14 (2013.01); A61L 29/16 (2013.01); A61M 25/10 (2013.01); C12N 15/113 (2013.01); A61K 9/5031 (2013.01); A61L 2300/258 (2013.01); A61L 2300/416 (2013.01); A61L 2300/606 (2013.01); A61L 2300/608 (2013.01); A61L 2300/62 (2013.01); A61L 2300/802 (2013.01); A61L 2420/06 (2013.01); A61L 2420/08 (2013.01); A61M 2025/105 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01)] 14 Claims
 
1. A drug delivery coating comprising
a base polymeric layer, the base polymeric layer comprising a hydrophilic surface;
a therapeutic agent layer forming an exterior surface of the drug delivery coating, the therapeutic agent layer contacting the hydrophilic surface of the base polymeric layer and having a composition different than the base polymeric layer, the therapeutic agent layer comprising
a hydrophobic therapeutic agent comprising rapamycin or a rapamycin analogue; and
a cationic agent;
wherein a ratio (wt./wt.) of particulate hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 90/10.